for people ages 18 years and up (full criteria)
at Orange, California and other locations
study started
estimated completion



The purpose of the current study is to assess safety/tolerability and key pharmacodynamic (PD) effects that are considered to be associated with clinical benefit (reduction of total IgG and anti-AChR-IgG) in Myasthenia Gravis patients following treatment with RVT-1401 (also known as IMVT-1401) compared to placebo.

Official Title

A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension of RVT-1401 in Myasthenia Gravis Patients


Myasthenia Gravis IMVT-1401 Muscle Weakness RVT-1401


You can join if…

Open to people ages 18 years and up

  1. Male or female ≥ 18 years of age.
  2. Myasthenia Gravis Foundation of America (MGFA) Class II-IVa and likely not in need of a respirator for the duration of the study as judged by the Investigator.
  3. QMG score ≥12 at Screening and Baseline.

Other, more specific inclusion criteria are defined in the protocol.

You CAN'T join if...

  1. Use of rituximab, belimumab, eculizumab or any monoclonal antibody for immunomodulation within 6 months prior to first dosing.
  2. Immunoglobulins given by SC, IV (IVIG), or intramuscular route, or plasmapheresis/plasma exchange (PE) within 4 weeks before Screening.
  3. Thymectomy performed < 12 months prior to screening.
  4. Total IgG level <6 g/L (at screening).
  5. Absolute neutrophil count <1500 cells/mm3(at screening).

Other, more specific exclusion criteria are defined in the protocol


  • UC Irvine - MDA ALS and Neuromuscular Center accepting new patients
    Orange California 92868 United States
  • Phoenix Neurological Associates accepting new patients
    Phoenix Arizona 85018 United States


accepting new patients
Start Date
Completion Date
Immunovant Sciences GmbH
Phase 2
Study Type
Last Updated